Publications
Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleGhani R, Mullish BH, Roberts LA, et al., 2022,
The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
, Gut Microbes, Vol: 14, ISSN: 1949-0976 -
Journal articlePowles STR, Gallagher KI, Chong LWL, et al., 2022,
Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome
, BMC Gastroenterology, ISSN: 1471-230X -
Journal articleGhani R, Mullish BH, Davies FJ, et al., 2022,
How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection
, Clinical Microbiology and Infection, Vol: 28, Pages: 502-512, ISSN: 1198-743X -
Journal articleMullish BH, McDonald JAK, Marchesi JR, 2022,
Mechanisms of efficacy of intestinal microbiota transplant: do not forget the metabolites
, The Lancet Gastroenterology & Hepatology, ISSN: 2468-1253 -
Journal articleFromentin S, Forslund SK, Chechi K, et al., 2022,
Microbiome and metabolome features of the cardiometabolic disease spectrum
, NATURE MEDICINE, Vol: 28, Pages: 303-+, ISSN: 1078-8956- Author Web Link
- Cite
- Citations: 16
-
Journal articleTalmor-Barkan Y, Bar N, Shaul AA, et al., 2022,
Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease
, NATURE MEDICINE, Vol: 28, Pages: 295-+, ISSN: 1078-8956- Author Web Link
- Cite
- Citations: 11
-
Journal articleForlano R, Mullish BH, Roberts LA, et al., 2022,
The intestinal barrier and its dysfunction in patients with metabolic diseases and non-alcoholic fatty liver disease
, International Journal of Molecular Sciences, Vol: 23, ISSN: 1422-0067Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease worldwide, mirroring the epidemics of obesity and metabolic syndrome. As there are still no licensed medications for treating the disease, there is an ongoing effort to elucidate the pathophysiology and to discover new treatment pathways. An increasing body of evidence has demonstrated a crosstalk between the gut and the liver, which plays a crucial role in the development and progression of liver disease. Among other intestinal factors, gut permeability represents an interesting factor at the interface of the gut–liver axis. In this narrative review, we summarise the evidence from human studies showing the association between increased gut permeability and NAFLD, as well as with type-2 diabetes and obesity. We also discuss the manipulation of the gut permeability as a potential therapeutical target in patients with NAFLD.
-
Journal articleRadhakrishnan ST, Alexander JL, Mullish BH, et al., 2022,
Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease
, Alimentary Pharmacology & Therapeutics, Vol: 55, Pages: 26-48, ISSN: 0269-2813 -
Journal articleBiliński J, Winter K, Jasiński M, et al., 2022,
Rapid resolution of COVID-19 after faecal microbiota transplantation.
, Gut, Vol: 71, Pages: 230-232 -
Journal articleForslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al., 2021,
Combinatorial, additive and dose-dependent drug-microbiome associations
, NATURE, Vol: 600, Pages: 500-+, ISSN: 0028-0836
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.